Paid Clinical Trials Saint Paul

Discover 1,030 paid clinical trials in Saint Paul, Minnesota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,030

Tertiary Prevention of Child Sexual AbuseTertiary Prevention of Child Sexual Abuse

Recruiting

Sponsor:

University of Minnesota

Location:

Minneapolis MN

Code:

NCT06126926

Conditions

Child Sexual Abuse

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

group therapy

Treatment as usual

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

Recruiting

PHASE3

Sponsor:

Chimerix

Location:

Minneapolis MN, Rochester MN, Madison WI, Iowa City IAshow 53 more

Code:

NCT05580562

Conditions

H3 K27M

Glioma

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Dordaviprone (ONC201)

Dordaviprone (ONC201) + Placebo

Placebo

SMART Exercise for PADSMART Exercise for PAD

Recruiting

PHASE3

Sponsor:

Northwestern University

Location:

Minneapolis MN, Chicago IL

Code:

NCT06032065

Conditions

Peripheral Arterial Disease

Aging

Peripheral Vascular Diseases

Walking, Difficulty

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

Supervised Treadmill Exercise

Home-Based Exercise

Nitrate-rich beetroot Juice

Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight InfantsPercutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Recruiting

Sponsor:

Nationwide Children's Hospital

Location:

Minneapolis MN, Milwaukee WI, Chicago IL, Saint Louis MOshow 17 more

Code:

NCT05547165

Conditions

Ductus Arteriosus, Patent

Eligibility Criteria

Sex: All

Age: 7 - 32

Healthy Volunteers: Not accepted

Interventions

Percutaneous Patent Ductus Arteriosus Closure (PPC)

Responsive Management Intervention

Echocardiogram, cardiac

Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12Safety of Extending The Routine Flushing Of Implanted Port Devices From 4 Weeks To 12

Recruiting

Sponsor:

Essentia Health

Location:

Monticello MN, Princeton MN, Mankato MN, Sandstone MNshow 12 more

Code:

NCT05454189

Conditions

Maintenance of Implanted Port Devices

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Reduced IPD Flush Schedule

Standard IPD Flush Schedule

A Research Study to Advance the CF Therapeutics Pipeline for People Without ModulatorsA Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

Recruiting

Sponsor:

Nicole Hamblett

Location:

Minneapolis MN, Madison WI, Omaha NE, Chicago ILshow 58 more

Code:

NCT06504589

Conditions

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCTo Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting

PHASE3

Sponsor:

Shanghai Henlius Biotech

Location:

Saint Paul MN, Madison WI, Milwaukee WI, Omaha NEshow 85 more

Code:

NCT05468489

Conditions

Extensive Stage Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Serplulimab + chemotherapy (carboplatin-etoposide)

Atezolizumab + chemotherapy (carboplatin-etoposide)

Alport Syndrome Treatments and Outcomes RegistryAlport Syndrome Treatments and Outcomes Registry

Recruiting

Sponsor:

University of Minnesota

Location:

Minneapolis MN

Code:

NCT00481130

Conditions

Alport Syndrome

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Saint Paul MN, Maplewood MN, Woodbury MN, Minneapolis MNshow 706 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIMA Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM

Recruiting

PHASE3

Sponsor:

Laboratoire français de Fractionnement et de Biotechnologies

Location:

Minneapolis MN, Atlanta GA, New Orleans LA, Houston TXshow 1 more

Code:

NCT05695391

Conditions

Hemophilia

Eligibility Criteria

Sex: Male

Age: 12 - 65

Healthy Volunteers: Not accepted

Interventions

Coagulation Factor VIIa (Recombinant)